Success Metrics

Clinical Success Rate
91.3%

Based on 21 completed trials

Completion Rate
91%(21/23)
Active Trials
1(4%)
Results Posted
52%(11 trials)
Terminated
2(7%)

Phase Distribution

Ph phase_4
4
15%
Ph not_applicable
2
7%
Ph phase_1
2
7%
Ph phase_3
9
33%
Ph phase_2
7
26%

Phase Distribution

2

Early Stage

7

Mid Stage

13

Late Stage

Phase Distribution24 total trials
Phase 1Safety & dosage
2(8.3%)
Phase 2Efficacy & side effects
7(29.2%)
Phase 3Large-scale testing
9(37.5%)
Phase 4Post-market surveillance
4(16.7%)
N/ANon-phased studies
2(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.3%

21 of 23 finished

Non-Completion Rate

8.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

27

all time

Status Distribution
Active(1)
Completed(21)
Terminated(2)
Other(3)

Detailed Status

Completed21
unknown3
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
1
Success Rate
91.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (8.3%)
Phase 27 (29.2%)
Phase 39 (37.5%)
Phase 44 (16.7%)
N/A2 (8.3%)

Trials by Status

unknown311%
completed2178%
terminated27%
recruiting14%

Recent Activity

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT05103332Phase 2

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

Completed
NCT05917275Phase 4

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

Recruiting
NCT05189015Phase 4

Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension

Completed
NCT04606563Phase 3

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated
NCT04856969Phase 1

Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers

Completed
NCT01870739Phase 2

A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

Completed
NCT03655964Phase 2

Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke

Completed
NCT02449811

RAS Peptide Profiles in Patients With Arterial Hypertension

Completed
NCT02373462Phase 4

Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)

Terminated
NCT03560804Not Applicable

Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs

Completed
NCT01785472Phase 3

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Completed
NCT02996916Phase 4

Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue

Unknown
NCT01692301Phase 2

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Completed
NCT01876368Phase 3

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Completed
NCT01615198Phase 3

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Completed
NCT01599104Phase 3

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Completed
NCT02516826Phase 2

The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease

Unknown
NCT00122447Not Applicable

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

Completed
NCT01764295Phase 3

Clinical Study for Patients With Hypertension Associated With Dyslipidemia

Completed
NCT01831479Phase 1

Investigation of Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan in Healthy Male Volunteers

Completed

Drug Details

Intervention Type
DRUG
Total Trials
27